Navigation Links
Tandem Labs' New England Facility Doubles Discovery Support Capacity - Increasing Foothold in New England
Date:10/9/2007

WOBURN, Mass., Oct. 9 /PRNewswire/ -- Tandem Labs, a leading contract research organization (CRO) providing bioanalytical, immunoanalytical, and pharmacokinetic (PK)/pharmacodynamic (PD) services to the pharmaceutical industry, announced that it has acquired additional MDS SCIEX API 5000(TM) and 4000(TM) LC/MS/MS systems for its New England facility in Woburn, Massachusetts. This acquisition doubles the facility's current triple quadrupole LC/MS/MS capacity, allowing it to better serve its clientele through this expansion in capacity.

"Tandem Labs acquired these additional instruments to further increase our capacity in the critical New England region," said Denis C.K. Lin, Ph.D., president and CEO. "These assets will significantly enhance our reach within the drug discovery and development industry, particularly in Massachusetts as well as other Northeast states."

The New England operation is focused upon providing rapid turnaround non- GLP discovery PK/PD services in addition to metabolite identification and biomarker services. Combined with other advanced mass spectrometric platforms beyond the triple quadrupoles, the New England facility also uses proprietary informatics to reduce the difficulty, complexity, and time-consuming nature of developing and launching a drug to market. DMDiscovery(TM) is a drug metabolism technology that increases the productivity of drug metabolite identification and quantification. MarkerScan(TM) is a biomarker discovery and screening process that efficiently identifies potential biomarkers that can be used to increase the understanding of disease, diagnosis, and predictive models as well as drug compound safety, efficacy, and side-effect profiles.

Tandem Labs has additional facilities in Utah and New Jersey; the Utah location focuses primarily on GLP bioanalytical services and discovery support while the New Jersey location specializes in GLP-compliant bioanalysis on LC/MS/MS and immunoanalytical platforms.

About Tandem Labs

Tandem Labs is a leading CRO specializing in advanced mass spectrometry, immunoanalytical support, and PK/PD for the pharmaceutical/biotechnology industries in the United States and internationally. With more than 30 LC/MS/MS instruments and 54,000-square-feet available, Tandem Labs exists to serve the needs of its clients. By applying scientific ingenuity, responsive communication, flexible client service, disciplined compliance, and a commitment to information technology, Tandem supports drug discovery and development by offering a comprehensive suite of customizable services that help clients reduce their overall time in bringing new medicines to market.

For further information, contact:

Denis Lin, Ph.D.

President & CEO

Tandem Labs

(801) 293-2400

e-mail: denis.lin@tandemlabs.com

Jean Pineault, M.S.

Vice President, Sales & Marketing

Tandem Labs

(609) 228-0201

e-mail: jean.pineault@tandemlabs.com


'/>"/>
SOURCE Tandem Labs
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Grants worth $800,000 help BellBrook Labs develop products
2. Abbott Labs campus in Kenosha could send ripples through local biotech
3. BellBrook Labs gets major research funding
4. GE Healthcare wins $200m slice of Englands digital health-care plan
5. New Mexico firm to make flu vaccine at Wisconsin BioManufacturing facility
6. Medical College dedicates $140M research facility
7. Ethanol plant builder to expand Merrill facility
8. GE Healthcare opens facility meant for 2,000 employees
9. New company eyes major ethanol production facility
10. GE Healthcare invests $37.5 million in Chinese bio-sciences manufacturing facility
11. PDS sees Madison facility as launchpad for growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/18/2017)... , Jan. 18, 2017 Applied BioMath ... modeling to drug research and development, today announced ... President, and CEO of Applied BioMath, will present ... and Modeling (BAGIM) Meeting on Thursday January 19, ... Cambridge , MA.   Dr. Burke,s talk "Quantitative ...
(Date:1/18/2017)... ... 18, 2017 , ... Whitehouse Labs has furthered its efforts ... Inc. (AMRI), the scientific staff dedicated to Extractables / Leachables & Impurities has ... in 2017. Extractable & Leachable evaluations have become increasingly more vital to successful ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... the CHI SCOPE Summit for Clinical Ops Executives (Hyatt Regency Miami, January 24-26). ... to examine vital clinical research issues such as trial performance metrics, patient enrollment ...
(Date:1/18/2017)... -- Shareholder rights law firm Johnson & Weaver, LLP ... of CoLucid Pharmaceuticals, Inc. (NASDAQ: CLCD ) ... sale of the Company to Eli Lilly and Company. ... for the acute treatment of migraines. On ... definitive merger agreement with Eli Lilly. Under the terms ...
Breaking Biology Technology:
(Date:1/11/2017)... Jan. 11, 2017  Michael Johnson, co-founder of Visikol Inc. a ... Inc., has been named to the elite "Forbes 30 Under 30" ... of 600 people in 20 fields nationwide to be recognized as ... 15,000 applicants were selected. ... He is currently a PhD candidate at Rutgers University. ...
(Date:1/4/2017)... LAS VEGAS , Jan. 4, 2017  For the thousands of ... , a global leader in connected health and biometric measurement devices and ... pressure monitors. On display in A&D Medical,s special CES ... monitors represent the ongoing expansion of the company,s WellnessConnected product ... ...
(Date:12/22/2016)... December 22, 2016 SuperCom (NASDAQ: ... solutions for the e-Government, Public Safety, HealthCare, and Finance sectors announced ... has been selected to implement and deploy a community-based supportive services ... Northern California , further expanding its presence in the state. ... This new program, ...
Breaking Biology News(10 mins):